Insiders Trades
Vivos Inc Stock: price and insider trades · United States
2 insiders bought €102k of shares over the last 90 days, the latest filed 01 Oct 2026.
Vivos Inc: what insiders have been doing
This page follows insider dealings at Vivos Inc as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. 2 insiders have disclosed 14 filings since 18 October 2025.
No insider sold shares on the market over the period. Instead, the filings list 12 purchases totalling €139k, made by 2 insiders. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The largest single trade was a purchase of €88k by Korenko Michael K, published on 1 October 2026, equal to 0.42% of the market capitalisation. Those buying include 2 chief executives.
In the case of 6 purchases, another manager of the company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The latest purchase is recent: it was published 17 days ago, on 1 October 2026. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4.
Across the 5,812 companies tracked on its exchange, the median is 19 filings; at 14 filings, this issuer sits below that mark. The full history, which starts in 2021, counts 26 purchases against 2 sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Cytosorbents Corp. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
34
Thresholds
n/a
Buy Volume
€232,739
26 ops. · all time
Sell Volume
€8,562
2 ops. · all time
Who traded when
BuySaleBrad Allan Weeks8 buys
Michael K. Korenko7 buys
Since the insiders bought
- -7.4%Entry US$0.05 · Close 14 Oct 2026 US$0.05
- -7.4%Entry US$0.05 · Close 14 Oct 2026 US$0.05
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 23,796 of 24,148 companies
8.4
score / 100
Value16
Quality1
FCF yld-9.0%
Earn yld-13%
EV/EBITDA·
ROE-133%
Gross mgn-87%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.05
Analyst consensus
Income statement
RevenueUS$68.4k
Gross profit-US$59.8k-87% margin
EBITDA-US$3.2M-4628% margin
Net income-US$3.1M-4483.9% margin
Valuation
Beta-0.55
Balance sheet & cash
Market capUS$23.7M
Total debtUS$114.3k
Free Cash Flow-US$2.2M
Debt / Equity4%
Profitability & ownership
ROE-132.5%
ROA-62.5%
% insiders4.6%
% institutions0.0%
Last declaration on 1 October 2026
Declarations34 total
200,000 shares@ US$0.4980.42% mcap31.0% of flowCommon StockSEC:0001486806-26-000010:0
Canonical exit: 29 Dec 2026 (T+90)
25,550 shares@ US$0.04820.0053% mcap9.1% of flowCommon StockSEC:0002131351-26-000014:0
Canonical exit: 15 Dec 2026 (T+90)
150,000 shares@ US$0.05310.034% mcap3.5% of flowCommon StockSEC:0001486806-26-000008:0
Canonical exit: 8 Nov 2026 (T+90)
50,000 shares@ US$0.05480.012% mcap20.3% of flowCommon StockSEC:0002131351-26-000012:0
Canonical exit: 8 Nov 2026 (T+90)
60,000 shares@ US$0.050.013% mcap22.5% of flowCommon StockSEC:0002131351-26-000010:0
Canonical exit: 19 Oct 2026 (T+90)
32,000 shares@ US$0.050.0069% mcap12.0% of flowCommon StockSEC:0002131351-26-000010:1
Canonical exit: 20 Oct 2026 (T+90)
147,159 shares0Common StockSEC:0002131351-26-000008:1
100,111 shares0Common StockSEC:0002131351-26-000008:0
200,000 shares@ US$0.05710.049% mcap5.1% of flowCommon StockSEC:0001486806-26-000006:0
Canonical exit: 13 Oct 2026 (T+90)
48,000 shares@ US$0.080.017% mcap28.8% of flowCommon StockSEC:0002131351-26-000004:0
Canonical exit: 7 Oct 2026 (T+90)
12,000 shares@ US$0.080.0041% mcap7.2% of flowCommon StockSEC:0002131351-26-000004:1
Canonical exit: 8 Oct 2026 (T+90)
200,000 shares@ US$0.06465.6% of flowCommon StockSEC:0001486806-26-000002:0
Canonical exit: 31 Mar 2026 (T+90)
100,000 shares@ US$0.07223.2% of flowCommon StockSEC:0001486806-25-000006:0
Canonical exit: 2 Mar 2026 (T+90)
100,000 shares@ US$0.06222.8% of flowCommon StockSEC:0001486806-25-000004:0
Canonical exit: 18 Feb 2026 (T+90)
100,000 shares@ US$0.07663.4% of flowCommon StockSEC:0001415889-25-021810:0
Canonical exit: 12 Nov 2025 (T+90)
50,000 shares@ US$0.14163.3% of flowCommon StockSEC:0001415889-24-025674:0
Canonical exit: 26 Jan 2025 (T+90)
50,000 shares@ US$0.15913.6% of flowCommon StockSEC:0001415889-24-024085:0
Canonical exit: 29 Dec 2024 (T+90)
50,000 shares@ US$0.11192.6% of flowCommon StockSEC:0001415889-24-021126:0
Canonical exit: 11 Nov 2024 (T+90)
50,000 shares@ US$0.11762.7% of flowCommon StockSEC:0001415889-24-020862:0
Canonical exit: 5 Nov 2024 (T+90)
50,000 shares@ US$0.08722.1% of flowCommon StockSEC:0001415889-24-020572:0
Canonical exit: 30 Oct 2024 (T+90)
50,000 shares@ US$0.09352.2% of flowCommon StockSEC:0001415889-24-020244:0
Canonical exit: 27 Oct 2024 (T+90)
50,000 shares@ US$0.16874.0% of flowCommon StockSEC:0001415889-24-015308:0
Canonical exit: 2 Sept 2024 (T+90)
100,000 shares@ US$0.05172.5% of flowCommon StockSEC:0001415889-23-015057:0
Canonical exit: 11 Feb 2024 (T+90)
100,000 shares@ US$0.05362.6% of flowCommon StockSEC:0001415889-23-014424:0
Canonical exit: 16 Jan 2024 (T+90)
16,000 shares@ US$0.0624100.0% of flowCommon StockSEC:0001415889-23-005431:0
25 of 34 declarations
About Vivos Inc
Vivos Inc. (ticker: RDGL) is a U.S.-based medical technology company with a profile that remains materially different from a mature commercial medtech group. In the latest SEC filings reviewed, the stock is described as quoted on the OTCQB marketplace under RDGL rather than on NYSE or NASDAQ. The company is organized in the United States and has its principal operating presence in Richland, Washington, in the U.S. Pacific Northwest. Its corporate history dates back to 1994, when it was incorporated as Savage Mountain Sports Corporation, later renamed Advanced Medical Isotope Corporation in 2006, and finally Vivos Inc. in 2017. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1449349/000149315226008813/partiiandiii.htm?utm_source=openai))
Strategically, Vivos operates in precision oncology and more specifically in intratumoral radiation therapy devices. Its core platform is a proprietary hydrogel-based yttrium-90 technology marketed under the RadioGel™ brand for human use and IsoPet® for veterinary applications. The company describes this as an injectable precision radionuclide therapy intended to deliver radiation directly inside the tumor, with the goal of limiting exposure to healthy surrounding tissue. In practical terms, the addressable use cases highlighted by the company are non-resectable and radiation-resistant tumors, alongside selected companion-animal cancers. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1449349/000149315224025735/ex99-1.htm))
Read moreShow less
From an investment standpoint, Vivos should still be viewed as a development-stage company with limited revenues and a high execution risk profile. The SEC filings indicate recurring losses since inception and ongoing dependence on equity financing, debt financing, grants, and Regulation A+ offerings. The company qualified a new Regulation A+ offering in March 2026 for up to $75 million, following earlier offerings in 2023, 2024, and 2025. For investors in France, Belgium, or Switzerland, the key takeaway is that Vivos is primarily a regulatory and clinical milestone story rather than a company already driven by scaled commercial sales. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1449349/000149315226023146/form10-q.htm))
Its competitive appeal lies in a differentiated therapeutic concept: localized radiation delivery, potential outpatient administration, and a platform that could span both human and veterinary oncology. The company said it received FDA Breakthrough Device Designation in December 2023 and filed an Investigational Device Exemption submission in June 2024 to advance first-in-human clinical trials. More recent SEC disclosures in 2026 discuss preparations for human studies in the U.S. and India, together with the formation of Vivos Scientific India LLP to support manufacturing, clinical data generation, and eventual commercialization in India. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1449349/000149315224025735/ex99-1.htm))
Geographically, the business remains centered in the United States, with historical roots in Washington State and a current commercial emphasis on the animal-therapy market in the Northwestern U.S. Internationally, the company is still early in its expansion path, but India is now an explicit strategic focus through licensing, product transfer, and local development efforts. Overall, Vivos Inc. fits the profile of a speculative U.S. healthcare micro-cap: technologically interesting, potentially disruptive, but highly exposed to regulatory approvals, financing needs, and operational execution. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1449349/000149315226023146/form10-q.htm))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
